Fixed-time chlorazepate dipotassium premedication versus midazolam on demand: a randomised, controlled trial

ISRCTN ISRCTN39991569
DOI https://doi.org/10.1186/ISRCTN39991569
Protocol serial number N/A
Sponsor University Hospital Schleswig-Holstein (Germany)
Funder University Hospital Schleswig-Holstein (Germany)
Submission date
13/12/2006
Registration date
13/02/2007
Last edited
26/03/2021
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Surgery
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Patrick Meybohm
Scientific

University Hospital Schleswig-Holstein
Campus Kiel
Schwanenweg 21
Kiel
24105
Germany

Email meybohm@anaesthesie.uni-kiel.de

Study information

Primary study designInterventional
Study designRandomised double-blind placebo-controlled study
Secondary study designRandomised controlled trial
Scientific titleFixed-time chlorazepate dipotassium premedication versus midazolam on demand: a randomised, controlled trial
Study acronympremedication
Study objectivesWe hypothesised that:
1. 50 mg chlorazepate dipotassium at 10 pm evening before surgery prevent an increase of anxiety and sympatho-adrenal activity at morning of surgery sufficiently, and
2. A fixed-time application of chlorazepate dipotassium at 7 am morning of surgery may be superior compared to administration of midazolam 30 minutes prior to induction of anesthesia with respect to level of anxiety, sympatho-adrenal activity and conscious sedation.
Ethics approval(s)The trial was approved by the local ethics committee of the University Kiel on the 3rd April 2002 (reference number: AZ 142/01).
Health condition(s) or problem(s) studiedPremedication, Anaesthesia
InterventionPatients were randomised to one of two groups:
1. Group CCP: at Evening Before Surgery (EBS) clorazepate dipotassium 50 mg orally (Tranxilium®; Sanofi-Aventis GmbH, Frankfurt am Main, Germany); at Morning Of Surgery (MOS) clorazepate dipotassium 25 mg orally; and before Induction of Anesthesia (AI) placebo orally
2. Group CPM: at EBS clorazepate dipotassium 50 mg orally; at MOS placebo orally; before AI midazolam 7.5 mg orally (Dormicum®; Roche, Mijdrecht, The Netherlands)

Dosages of clorazepate dipotassium in our study were based on recommendations that have been published previously.
Intervention typeDrug
PhaseNot Specified
Drug / device / biological / vaccine name(s)Chlorazepate dipotassium and midazolam
Primary outcome measure(s)

1. Level of anxiety
2. Sympatho-adrenal activity (plasma levels of Adrenocorticotropic Hormone [ACTH], cortisol, norepinephrine and epinephrine)

Key secondary outcome measure(s)

1. Haemodynamic data
2. Oxygen saturation
3. Conscious sedation
4. Bispectral index

Completion date01/10/2004

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexNot Specified
Target sample size at registration50
Total final enrolment50
Key inclusion criteria1. Patients with an American Society of Anaesthesiologists (ASA) physical status of one or two
2. Aged between 18 and 55 years
3. Weighing from 60 to 88 kg
4. Scheduled to undergo an elective surgical, orthopaedic or urologic procedure in general anesthesia
Key exclusion criteria1. Sleep apnoea syndrome
2. Pregnancy
3. Use of sedative, stimulant, or other medications within the previous month
4. The presence of neurological, renal, or hepatic disease
Date of first enrolment01/05/2003
Date of final enrolment01/10/2004

Locations

Countries of recruitment

  • Germany

Study participating centre

University Hospital Schleswig-Holstein
Kiel
24105
Germany

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article 01/09/2007 26/03/2021 Yes No

Editorial Notes

26/03/2021: The following changes were made to the trial record:
1. Publication reference added.
2. The total final enrolment was added.